EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

Maddalena Centanni, Omar Zaher, David Elhad, Mats O Karlsson, Lena E Friberg iD

Cancer Chemotherapy and Pharmacology · 2024-08 · 94 (2) · 297-310

DOI: 10.1007/s00280-024-04678-0 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 23.05.2024. Verfasst von Maddalena Centanni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Box 580, Uppsala, 751 23, Sweden. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Models, Biological, Pyrimidines, Sunitinib. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uppsala University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Model-based methods can predict pediatric exposure and support initial dose selection. The aim of this study was to evaluate the performance of allometric scaling of population pharmacokinetic (popPK) versus physiologically based pharmacokinetic (PBPK) models in predicting the exposure of tyrosine kinase inhibitors (TKIs) for pediatric patients (≥ 2 years), based on adult data. The drugs imatinib, sunitinib and pazopanib were selected as case studies due to their complex PK profiles including high inter-patient variability, active metabolites, time-varying clearances and non-linear absorption.

Methods

Pediatric concentration measurements and adult popPK models were derived from the literature. Adult PBPK models were generated in PK-Sim® using available physicochemical properties, calibrated to adult data when needed. PBPK and popPK models for the pediatric populations were translated from the models for adults and were used to simulate concentration-time profiles that were compared to the observed values.

Results

Ten pediatric datasets were collected from the literature. While both types of models captured the concentration-time profiles of imatinib, its active metabolite, sunitinib and pazopanib, the PBPK models underestimated sunitinib metabolite concentrations. In contrast, allometrically scaled popPK simulations accurately predicted all concentration-time profiles. Trough concentration (C trough ) predictions from the popPK model fell within a 2-fold range for all compounds, while 3 out of 5 PBPK predictions exceeded this range for the imatinib and sunitinib metabolite concentrations.

Conclusion

Based on the identified case studies it appears that allometric scaling of popPK models is better suited to predict exposure of TKIs in pediatric patients ≥ 2 years. This advantage may be attributed to the stable enzyme expression patterns from 2 years old onwards, which can be easily related to adult levels through allometric scaling. In some instances, both methods performed comparably. Understanding where discrepancies between the model methods arise, can further inform model development and ultimately support pediatric dose selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsModels, BiologicalPyrimidinesSunitinibIndazolesSulfonamidesImatinib MesylateHumansChildAdultChild, PreschoolAdolescentComputer SimulationMaleFemaleAntineoplastic AgentsAge Factors

Stichwörter der Autor:innen

Allometric scalingPediatric pharmacokineticsPhysiologically based pharmacokinetic modelingTyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsPyrimidinesSunitinibIndazolesSulfonamidespazopanibImatinib MesylateAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Uppsala University, Box 580, Uppsala, 751 23, Sweden.
  • Department of Pharmacy, Uppsala University, Box 580, Uppsala, 751 23, Sweden. lena.friberg@farmaci.uu.se.

ORCID-Profile: Lena E Friberg

Förderung

  • Uppsala University

Zitieren

APA

Centanni, M., Zaher, O., Elhad, D., Karlsson, M. O., & Friberg, L. E. (2024). Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children. Cancer Chemotherapy and Pharmacology, 94(2), 297-310. https://doi.org/10.1007/s00280-024-04678-0

Vancouver

Centanni M, Zaher O, Elhad D, Karlsson MO, Friberg LE. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children. Cancer Chemotherapy and Pharmacology. 2024;94(2):297-310. doi:10.1007/s00280-024-04678-0

BibTeX
@article{Centanni2024,
  author = {Centanni, Maddalena and Zaher, Omar and Elhad, David and Karlsson, Mats O and Friberg, Lena E},
  title = {Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  volume = {94},
  number = {2},
  pages = {297--310},
  doi = {10.1007/s00280-024-04678-0}
}
Kostenlos starten →